BBIO · BridgeBio Pharma Inc
Price
Snapshot
50 fields · last close| Market Cap | $13.21B |
| P/E | — |
| Float | 171.5M |
| Beta | 0.95 |
| Volatility | 23.7% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 74.5 |
| Price | 68.60 |
| Change | +1.55% |
| Prev Close | 67.55 |
| Open | 68.28 |
| Day Low | 67.25 |
| Day High | 69.00 |
| Avg Vol | 3 |
| Avg $ Vol | $170.0M |
| 52W High | 93.42 |
| 52W Low | 52.75 |
| 52W Pos | 39.0% |
| From High | −26.56% |
| From Low | +30.05% |
| Max DD 1Y | −29.80% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +3.70% |
| SMA 50 | −5.08% |
| SMA 200 | −6.01% |
| RSI (14) | 48.5 |
| Vol 30D | 37.1% |
| Vol 90D | 39.6% |
| 1Y Range | 53–93 |
| Daily bars | 900 |
| Perf Week | +6.71% |
| Perf Month | +1.46% |
| Perf Quarter | −18.28% |
| Perf Half Y | −11.33% |
| Perf Year | +23.00% |
| Perf YTD | −12.32% |
| Prev Day | +1.55% |
| Clavix | B |
| Debt / Eq | 8.27 |
| Curr Ratio | 2.77 |
| Int Cover | -1.9× |
| FCF Margin | −89.0% |
| Rev Growth | +126.3% |
| Profit | Unprofitable |
| Leverage | Very High |
| Sector rank | 15 / 35 |
Clavix risk grade
regraded every trading dayBBIO grades B, 74.5 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (56, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 15 of 35 in Biotechnology by Clavix score.
How rough the ride is
| BBIO | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.95 | 0.51 |
| Volatilityannualized | 23.7% | 14.5% |
| Max drawdown, past yearworst peak-to-trough fall | −29.8% | — |
| Typical daily movemedian absolute daily change | 1.41% | — |
| Days beyond ±3%of the last 252 sessions | 51 (20%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BBIO | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.95 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BBIO | |
|---|---|
| 1 week | +6.7% |
| 1 month | +1.5% |
| Year to date | −12.3% |
| 1 year | +23.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BBIO | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 26 Aug |
| Average score0 most bearish, 100 most bullish | 64 |
| Bullish · bearisharticles above 60 · below 40 | 20 · 4 |
| Directionarticles whose tone is improving vs worsening | 20 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| BBIO | |
|---|---|
| Revenue growthyear over year | +126.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openUBS Group issued an opinion upgrading BridgeBio Pharma to a 'strong-buy' rating in a research note on Wednesday. No additional details about the rationale or price target were provided.
The FDA granted priority review to BridgeBio's (BBIO) filing for infigratinib as a treatment for achondroplasia, the most common form of dwarfism. The drug could become the first approved oral therapy for the condition.
BridgeBio's FDA filing for infigratinib, an oral pill for achondroplasia (the most common form of dwarfism), has been accepted for Priority Review, putting the agency on a faster decision track.
BridgeBio said the FDA accepted its application to approve oral infigratinib for children with achondroplasia (the most common form of dwarfism) and granted it Priority Review, giving the company a February 4, 2027 deadline for the FDA's decision. The company cited Phase 3 trial results showing children on the drug grew up to 2.10 cm more per year than those on placebo, with no participants stopping the drug due to side effects.
BridgeBio said the FDA accepted its application for oral infigratinib as a treatment for children with achondroplasia (a genetic form of dwarfism) and granted it Priority Review, with a target decision date of February 4, 2027. The company's late-stage PROPEL 3 trial met its main goal and key secondary goals.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| HALO | Halozyme Therapeutics Inc | B | $14.12B | 33.62 | 0.93 | Compare |
| NBIX | Neurocrine Biosciences Inc | B+ | $14.43B | 20.39 | 0.34 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $14.62B | 17.25 | 0.39 | Compare |
| EXEL | Exelixis Inc | B+ | $15.95B | 18.43 | 0.44 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $10.80B | — | -1.08 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.63B | 40.03 | 0.65 | Compare |
| TWST | Twist Bioscience Corp | D+ | $9.39B | — | 2.19 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.93B | 107.38 | 1.20 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.